Xi'an export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 4 of 5 of this archive, newest first.
Follow the resin, not the catalogue.
The observation that closes a facility is rarely the dramatic one.
The document is four pages. Three of them are about dates.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A body-composition report gives four decimal places and no confidence interval. That is the whole difficulty in one sentence.
The denominator matters more than the ratio: per kilogram of body weight, of ideal weight, or of lean mass gives three different targets.
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Follow the resin, not the catalogue.
The route did not close because of a rule about peptides.
Reported from the sessions, and from the two hours afterwards.
The supplier has not disputed the finding. It has not explained the gap either.
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Every degradation pathway accelerates by orders of magnitude on reconstitution, because the solvent that lyophilisation removed is the reagent most of them need.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The document is four pages. Three of them are about dates.
The observation that closes a facility is rarely the dramatic one.
Reported from the analysis, not from a warning notice.
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
The evidence base is thin and the document says so, which is to its credit.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
Reported from the analysis, not from a warning notice.
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
A reader holding a certificate can work out what it does not cover in about ninety seconds, and that is a useful ninety seconds.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The supplier has not disputed the finding. It has not explained the gap either.
Reported from the sessions, and from the two hours afterwards.
What adding GIP activity does, on the current evidence, and what remains unresolved.
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The result is unremarkable. What the report omits is not.
The observation that closes a facility is rarely the dramatic one.
What the Journal asks when a document arrives unsigned, and what the answers have been.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
Follow the resin, not the catalogue.
The evidence base is thin and the document says so, which is to its credit.